Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine
Themis Bioscience, a Vienna based biotech company, announced today the first clinical study worldwide of a live attenuated recombinant Zika vaccine tested in human volunteers. The vaccine is based on a well-established vaccine vector technology that uses a measles virus vaccine backbone. Previously the company succeeded in exploiting this technology for the development of a prophylactic Chikungunya vaccine. Following this success Themis quickly adapted the proprietary technology for the development of the Zika vaccine that now will be tested in a Phase I trial (MV-ZIKA-101).
Dr. Erich Tauber, CEO and founder of Themis explains: "We not only manage to initiated one of the first studies of Zika vaccines at all, but globally the first study to test a live attenuated recombinant Zika vaccine. Live attenuated vaccines are regarded as superior as they induce a faster and more complete activation of the immune system leading to durable immunity. We are happy to be at the forefront of developing such a powerful vaccine against Zika."
The clinical study will focus on identifying the most suitable doses of the vaccine candidate in regard to immunogenicity, safety, and tolerability. Therefore up to 48 healthy volunteers will participate in the study and three different treatment regimens will be compared with a placebo treatment. One treatment group will receive one injection of high dose vaccine, the other two groups will receive two shots of either high dose or low dose vaccine. Safety will be measured according to the occurrence of adverse events and side effects of the study medication. Efficacy will be detected by evaluating the elucidation of a Zika-specific immune response. Results of all groups are expected within the next six months. The study will be conducted at the "Department of Clinical Pharmacology" and the "Institute of Specific Prophylaxis and Tropical Medicine" at the Medical University of Vienna, Austria. These site will be opened for enrolment during April and first volunteers are expected from 10. April.
The prophylactic Zika vaccine is based on a measles vector platform, where selected antigens from the Zika virus have been inserted into the well-established measles vaccine delivering those new antigens into the cells, thereby triggering a specific immune response against the Zika virus. As the measles vaccine has already proven its high efficacy and safety on well over a billion individuals over the last 30 – 40 years, it offers an excellent safety profile and a validated, cost-efficient production process. Based on this technology Themis already tested a number of candidate Zika vaccines in animal models, initiated a toxicity study and established GMP manufacturing. The promising results from the animal models advanced the now tested candidate rapidly to the clinical stage.
Zika is a viral infection transmitted by mosquitoes. It originates in Asia and parts of Africa but the increase in global traveling and rising temperatures may cause it to spread into more temperate zones. Recently, the virus spread across the Pacific Ocean to the Americas, leading to the 2015 – 16 Zika virus epidemic.
About the vaccine technology:
The core technology of the measles vector platform has been developed at the Institut Pasteur in Paris and is licensed to Themis. It relies on the use of the standard measles vaccine as a vaccination vector. Genes coding for selected antigens from the Zika virus have been inserted into the genome of this well-established vaccine. The measles-Zika vaccine delivers the Zika antigens directly to macrophages and dendritic cells – the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to Zika virus. This results in a powerful, antigen-focused immune response, which is most likely to confer long-term immunity as does the measles vaccine.
About Themis (April 2017):
Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected measles virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for all current vaccine candidates of the Vienna-based company.
Contact Themis Bioscience GmbH:
Dr. Erich Tauber
1190 Vienna, Austria
T +43 / 1 / 236 7151
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine here
News-ID: 499832 • Views: 483
More Releases from PR&D
Congenital Immunodeficiencies: Many Affected, Low Awareness; 15 Years of Joint P …
Outpatient immunology clinic in Vienna, Austria, a partner of the Jeffrey Modell Foundation for primary immunodeficiency disorders (PID) based in the US for the past 15 years; joint effort to increase awareness and improve health and quality of life of thousands of patients prone to serious infections. Vienna (Austria), August 21 2019 –. The successful partnership between the Immunologische Tagesklinik (ITK), a privately run outpatient immunology clinic in Vienna, and the
EU Healthcare Systems: a Reallocation Of Resources Is Urgently Needed
Turning away from “low-value” (waste, overuse) towards “high-value” health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel. Vienna, 11. July 2019 – On behalf of the European Commission, international health experts are now making a series of recommendations designed to place reallocation in healthcare systems on a real, value-based foundation. With the current pressure
contextflow selected for Philips HealthWorks AI in Radiology Accelerator
Deep learning expert contextflow GmbH thrilled to announce its participation in highly-selective program with one of the world’s leading health innovation companies Vienna, Austria, December 5th 2018 - contextflow, a recognized name in the highly competitive field of AI in medical image processing, is one of only 19 startups from 14 countries invited to participate in a 12-week “AI in Healthcare” startup-accelerator program spearheaded by Philips HealthWorks, a global leader in
More Releases for Zika
Zika Virus Vaccines Market 2022 | High rate of incidence of active Zika virus in …
Zika Virus Vaccines Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $18,697 million by 2022, registering a CAGR of 5.2% during the forecast period 2017-2022.Key opportunities include the need for vaccines for immunization & prevention of further spread of Zika virus infection and for treatment of Zika-linked birth defects. Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/1817 The outbreak of Zika virus infection in Latin
Zika Vaccines Market Size, Share, Development by 2023
New report published by Market Research Report Store (MRRS) which offers insights on the global Zika Vaccines market. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/212025/global-zika-vaccines-market Global Zika Vaccines Market: Forecast by Type / Application / Region According to this study, over the next five years the Zika Vaccines market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from
Zika Virus Testing Market Opportunity Assessment Research Study
One of the biggest public growing threat is the rapid emergence of mosquito borne virus called as Zika virus. Zika virus was first identified in rhesus monkey in the year 1947 in Uganda. Later in 1952 the virus was identified in humans. The virus is a single-stranded RNA virus of the Flaviviridae family, and is transmitted by two species of Aedes genus, Aedes aegypti and Aedes albopictus. These are the
Global Zika Virus Market Research Report 2017
Qyresearchreports include new market research report "Global Zika Virus Market Research Report 2017" to its huge collection of research reports. The global market for Zika Virus has been marked on several factors that are on the verge or have already impacted the growth of the market in several contexts. The report further pronounces different statistics and data pertaining to the global Zika Virus market. The core aim of the report is
Global Zika Virus Market Research Report 2017
The Global Zika Virus 2017 Market Research Report is a professional and in-depth study on the current state of the Zika Virus industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Zika Virus market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well
Zika Vaccines Market - Global Industry Insights 2025
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop